Comparison of Religious Cognitive Behavioral Therapy, Cognitive Behavioral Therapy, and Citalopram on Depression and Anxiety among Women with Breast Cancer: A Study Protocol for a Randomized Controlled Trial
Abstract
There has been evidence supporting the reduction of depression and anxiety by religious psychotherapy in cancer patients,
however, there have been scarce randomized controlled trials. Therefore, there is a need for replication in a well-designed
study to investigate the efficacy of these interventions among depressed women with breast cancer. A randomized
controlled trial is designed to be conducted on 160 women with breast cancer. Participants will be screened for anxiety
and depression diagnosed by clinical interview based on the DSM-IV criteria and the Hospital Anxiety Depression Scale.
Golriz and Baraheni’s Religious Attitude Questionnaire will be used to assess the religious attitude. Individuals meeting
the prerequisites will be randomly allocated to four groups, each containing 40 participants, including three intervention
groups (RCBT, CBT, and citalopram) and one control group (usual breast cancer treatment). An instrument by the
EORTCQLQ-C30 and BR-23 will be used to measure the quality of life. Blood tests will be taken to assess biomarkers with
the (ELISA) method. The results will determine whether RCBT is more effective than other treatments. If so, the outcomes
of the study will have implications not only for the management of similar problems in cancer patients but also for the
management of other chronic diseases.
Keywords
Full Text:
PDFReferences
Malvezzi M, Arfe A, Bertuccio P, Levi F, la Vecchia C, Negri
E. European cancer mortality predictions for the year 2011.
Annals of Oncology. 2011; 22(4):947–56.
Allemani C, Weir HK, Carreira H, Harewood R, Spika D,
Wang XS, et al. Global surveillance of cancer survival 1995-
: analysis of individual data for 25676887 patients from
population-based registries in 67 countries (CONCORD-
. Lancet. 2014 Nov 26.
O’Connor M, Christensen S, Jensen AB, Moller S, Zachariae
R. How traumatic is breast cancer? Post-traumatic stress
symptoms (PTSS) and risk factors for severe PTSS at 3 and
months after surgery in a nationwide cohort of Danish
women treated for primary breast cancer. Br J Cancer. 2011
Feb 1; 104(3):419–26.
Galloway SK, Baker M, Giglio P, Chin S, Madan A, Malcolm
R, et al. Depression and anxiety symptoms relate to distinct
components of pain experience among patients with breast
cancer. Pain Research and Treatment.2012; 2012:851276.
Olin JJ. Cognitive function after systemic therapy for breast
cancer. Oncology (Williston Park, NY). 2001; 15(5):613–8.
Meyers CA. How chemotherapy damages the central nervous
system. J Biol. 2008; 7(4):11.
Shibayama O, Yoshiuchi K, Inagaki M, Matsuoka Y, Yoshikawa
E, Sugawara Y, et al. Association between adjuvant regional
radiotherapy and cognitive function in breast cancer
patients treated with conservation therapy. Cancer Med.
Jun; 3(3):702–9.
Montazeri A. Health-related quality of life in breast cancer
patients: a bibliographic review of the literature from 1974
to 2007. Journal of Experimental andClinical Cancer Research.
; 27(1):32.
Faller H, Schuler M, Richard M, Heckl U, Weis J, Küffner
R. Effects of psycho-oncologic interventions on emotional
distress and quality of life in adult patients with cancer:
systematic review and meta-analysis.J Clin Oncol. 2013;
(6):787–93.
Blume J, Douglas SD, Evans DL. Immune suppression and
immune activation in depression. Brain, Behavior, and Immunity.
; 25(2):221–9.
Raison CL, Miller AH. Depression in cancer: new developments
regarding diagnosis and treatment. Biological Psychiatry.
; 54(3):283–94.
Raison CL, Capuron L, Miller AH. Cytokines sing the blues:
inflammation and the pathogenesis of depression. Trends
Immunol. 2006 Jan; 27(1):24–31.
Osborne L, Gispen F, Meilman S, Gocke A, Tosi D, Payne J.
Increased inflammatory markers in late pregnancy depression:
the role of progesterone and allopregnanolone. Brain,
Behavior, and Immunity. 2015; 49:22-3.
Roque S, Correia-Neves M, Mesquita AR, Palha JA, Sousa
N. Interleukin-10: a key cytokine in depression? Cardiovasc
Psychiatry Neurol. 2009; 2009:187894.
Gazal M, Jansen K, Souza LD, Oses JP, Magalhães PV, Pinheiro
R, et al. Association of interleukin-10 levels with age
of onset and duration of illness in patients with major depressive
disorder. Revista Brasileira de Psiquiatria. 2015;
(4):296–302.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L,
Reim EK, et al. A meta-analysis of cytokines in major depression.
Biol Psychiatry. 2010 Mar 1; 67(5):446–57.
Tavakoli-Ardakani M, Mehrpooya M, Mehdizadeh M, Hajifathali
A, Abdolahi A. Association between Interlukin-6
(IL-6), Interlukin-10 (IL-10) and depression in patients
undergoing hematopoietic stem cell transplantation. International
Journal of Hematology-Oncology and Stem Cell
Research. 2015; 9(2):80.
Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa
A, McGuire H, et al. Escitalopram versus other antidepressive
agents for depression. Cochrane Database Syst Rev.
;2.
Shiroma PR, Thuras P, Johns B, Lim KO. Emotion recognition
processing as early predictor of response to 8-week
citalopram treatment in late-life depression. Int J Geriatr
Psychiatry. 2014 Apr 4.
Lash TL, Pedersen L, Cronin-Fenton D, Ahern TP, Rosenberg
CL, Lunetta KL, et al. Tamoxifen’s protection against
breast cancer recurrence is not reduced by concurrent use of
the SSRI citalopram. Br J Cancer. 2008 Aug 19; 99(4):616–21.
Vol 8(S1) | 2016 | www.informaticsjournals.com/index.php/ajprhc Asian Journal of Pharmaceutical Research and Health Care
Comparison of Religious Cognitive Behavioral Therapy, Cognitive Behavioral Therapy, and Citalopram on Depression and
Anxiety among Women with Breast Cancer: A Study Protocol for a Randomized Controlled Trial
Rizzo M, Creed F, Goldberg D, Meader N, Pilling S. A systematic
review of non-pharmacological treatments for depression
in people with chronic physical health problems. J
Psychosom Res. 2011 Jul; 71(1):18–27.
Garlick M, Wall K, Corwin D, Koopman C. Psycho-spiritual
integrative therapy for women with primary breast
cancer. J Clin Psychol Med Settings. 2011 Mar;18(1):78–90.
Fallah R, Golzari M, Dastani M, Akbari ME. Integrating
spirituality into a group psychotherapy
program for women surviving from breast cancer. Iranian
Journal of Cancer Prevention. 2011; 4(3):141–3.
Olver IN, Dutney A. A randomized, blinded study of the
impact of intercessory prayer on spiritual well-being in patients
with cancer. Altern Ther Health Med. 2012 Sep-Oct;
(5):18–27.
Shaw B, Han JY, Kim E, Gustafson D, Hawkins R, Cleary J,
et al. Effects of prayer and religious expression within computer
support groups on women with breast cancer. Psycho-
Oncology. 2007; 16(7):676–87.
Koenig HG. Religious versus conventional psychotherapy
for major depression in patients with chronic medical illness:
rationale, methods, and preliminary results. Depress
Res Treat. 2012; 2012:460419.
Andrews JG, Oei TPS. The roles of depression and anxiety
in the understanding and treatment of obstructive
sleep apnea syndrome. Clinical Psychology Review. 2004;
(8):1031–49.
McGregora BA, Antonib MH. Psychological intervention
and health outcomes among women treated for breast cancer:
a review of stress pathways and biological mediators.
Brain, Behavior, and Immunity. 2009; 23(2):159–66.
Jafari N, Zamani A, Farajzadegan Z, Bahrami F, Emami H,
Loghmani A. The effect of spiritual therapy for improving
the quality of life of women with breast cancer: a randomized
controlled trial. Psychology, Health andMedicine.
;18(1):56–69.
Paiva CE, Paiva BS, deCastro RA, Souza CP, de Paiva Maia
YC, Ayres JA, et al. A pilot study addressing the impact of
religious practice on quality of life of breast cancer patients
during chemotherapy. J Relig Health. 2013 Mar; 52(1):184–
Ursaru M, Crumpei I, Crumpei G. Quality of life and religious
coping in women with breast cancer. Procedia - Social
and Behavioral Sciences. 2014 Feb21; 114:322–6.
Pearce M, Koenig HG. Cognitive behavioural therapy for
the treatment of depression in Christian patients with medical
illness. Mental Health, Religion and Culture. 2013;
(7):730–40.
Koenig HG. Religious versus conventional psychotherapy
for major depression in patients with chronic medical illness:
rationale, methods, and preliminary results. Depression
Research and Treatment. 2012;2012.
Pearce MJ, Koenig HG, Robins CJ, Nelson B, Shaw SF, Cohen
HJ, et al. Religiously integrated cognitive behavioral
therapy: A new method of treatment for major depression
in patients with chronic medical illness. Psychotherapy.
; 52(1):56.
Bayanzadeh S, Bolhary J, Dadfar M, Karimi Keisomi I. Effectiveness
of cognitive-behavioral religious-cultural therapy
in improvement of obsessive-compulsive patients. Razi
Journal of Medical Sciences. 2005; 11(44):913–23.
Bellinger D, Berk L, Koenig HG, Daher D, Pearce M, Robins
C, et al. Religious involvement, inflammatory markers
and stress hormones in major depression and chronic medical
illness.Open Journal of Psychiatry. 2014; 4(4):335–52.
Walpole SC, McMillan D, House A, Cottrell D, Mir G. Interventions
for treating depression in Muslim patients: a systematic
review. J Affect Disord. 2013 Feb 15; 145(1):11–20.
Lim C, Sim K, Renjan V, Sam HF, Quah SL. Adapted cognitive-
behavioral therapy for religious individuals with mental
disorder: a systematic review. Asian J Psychiatr. 2014
Jun; 9:3–12.
Sharifi V, Asadi SM, Mohammadi MR, Homayoun KHA,
Semnani Y, Shabanikia A, et al. Reliability and feasibility of
the Persian version of the structured diagnostic interview
for DSM-IV (SCID). Advances in Cognitive Science. 2004.
Montazeri A, Vahdaninia M, Ebrahimi M, Jarvandi S. The
hospital anxiety and depression scale (HADS): translation
and validation study of the Iranian version. Health and
Quality of Life Outcomes. 2003; 1(1):14.
Koenig H. Cognitive behavioral treatments for depression
in patients with chronic illness. Available from: wwwspiritualityand
health dukeedu//Full%20Protocol. 2014.
Sadeghi M, Ladari RB, Haghshenas M. A study of religious
attitude and mental health in students of Mazandaran University
of Medical Sciences. Journal of Mazandaran University
of Medical Sciences. 2010; 20(75):70–5.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull
A, Duez NJ, et al. The European organization for research
and treatment of cancer QLQ-C30: a quality-of-life instrument
for use in international clinical trials in oncology.
Journal of the National Cancer Institute. 1993; 85(5):365–
Hamid N, Behslideh K, Bayghi MA, Dehghanizadeh Z.
A study of the effect of religion-based cognitive-behavior
therapy on depression in divorced women. Journal of Family
Counseling andPsychotherapy. 2011; 1(1):54–64.
Kontodimopoulos N, Ntinoulis K, Niakas D. Validity of the
Greek EORTC QLQ-C30 and QLQ-BR23 for measuring
health-related quality of life in breast cancer patients. Eur J
Cancer Care (Engl). 2011 May; 20(3):354–61.
Montazeri A, Harirchi I, Vahdani M, Khaleghi F, Jarvandi S,
Ebrahimi M, et al. The EORTC breast cancer-specific quality
of life questionnaire (EORTC QLQ-BR23): translation
and validation study of the Iranian version. Quality of Life
Research. 2000; 9(2):177–84.
Sadeghi M, Ladari RB, Haghshenas M. A study of religious
attitude and mental health in students of Mazandaran university
of medical sciences. Journal of Mazandaran University
of Medical Sciences. 2010; 20:(75):70–5.
Beck J. Cognitive behavior therapy: basics and beyond. 2nd
ed. New York: Guilford Press; 2011.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
Listed as Green Publisher
Powered by Informatics India Ltd